Emergent Biosolutions Submits Proposal In Response To Hhs’ Rfp For Development And Procurement Of A Recombinant Protective Antigen Anthrax Vaccine
The company’s submission provides the U.S. Government with the critical option to select a domestic source to meet planned procurement of 25 million doses of rPA vaccine.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has submitted a proposal in response to a request for proposal (RFP) issued by the U.S. Department of Health and [...]
Posted on July 11, 2009 at 4:01 pm by admin · Permalink
· Leave a comment
In: Uncategorized · Tagged with: Clinical trial, Infectious disease, rPA 102, Strategic National Stockpile, United States, United States Department of Health and Human Services, US Food and Drug Administration, US government
In: Uncategorized · Tagged with: Clinical trial, Infectious disease, rPA 102, Strategic National Stockpile, United States, United States Department of Health and Human Services, US Food and Drug Administration, US government